Interim report, May–October 2020/21
Stable performance during Covid In Elekta’s second quarter, we managed to perform better than the overall radiotherapy market both in terms of orders and revenue despite continuous challenging circumstances. We also improved margins and stabilized cash flow. The launch of our new Harmony linac and regulatory clearances enhanced our product portfolio and strengthened our ability to deliver on our strategy of Precision Radiation Medicine. Gustaf SalfordPresident and CEOSecond quarter · Covid-19 continued to have a negative impact on Elekta’s growth in the quarter · Gross order